Printer Friendly

Browse Risankizumab topic

Risankizumab subtopic

Articles

1-25 out of 25 article(s)
Title Author Type Date Words
AbbVie wins US FDA clearance for SKYRIZI to treart moderate to severe plaque psoriasis in adults. Apr 24, 2019 295
AbbVie wins US FDA clearance for SKYRIZI to treart moderate to severe plaque psoriasis in adults. Apr 24, 2019 297
AbbVie wins US FDA clearance for SKYRIZI to treart moderate to severe plaque psoriasis in adults. Apr 24, 2019 299
AbbVie says FDA approves SKYRIZI. Apr 23, 2019 165
Abbvie (NYSE: ABBV) - AbbVie Announces First Regulatory Approval of SKYRIZI[TM] (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan - 26/3/2019. Apr 1, 2019 430
Japanese authorities approve AbbVie's SKYRIZI. Mar 28, 2019 179
Japanese authorities approve AbbVie's SKYRIZI. Mar 28, 2019 183
AbbVie passes MHLW approval for SKYRIZI for the treatment of psoriasis in Japan. Mar 26, 2019 297
AbbVie passes MHLW approval for SKYRIZI for the treatment of psoriasis in Japan. Mar 26, 2019 295
AbbVie passes MHLW approval for SKYRIZI for the treatment of psoriasis in Japan. Mar 26, 2019 293
AbbVie receives approval for SKYRIZI in Japan. Mar 26, 2019 124
Abbvie (NYSE: ABBV) - AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI[TM]) for the Treatment of Moderate to Severe Plaque Psoriasis -- 1/3/2019. Mar 4, 2019 352
AbbVie receives CHMP positive opinion for SKYRIZI. Mar 1, 2019 196
AbbVie announces patient reported outcome data for Phase 3 study of Risankizumab. Sep 13, 2018 208
Abbvie (NYSE: ABBV) - AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis -- 1/5/2018. May 7, 2018 245
AbbVie Seeks European Marketing Authorisation for Risankizumab for Treatment of Plaque Psoriasis. May 4, 2018 228
Abbvie (NYSE: ABBV) - AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis -- 25/4/2018. Apr 30, 2018 402
AbbVie Presents Positive Results from Phase 3 Trials of Risankizumab for Treatment of Psoriasis at 2018 Dermatology Meeting. Feb 20, 2018 331
AbbVie: Risankizumab meets all primary endpoints in Phase 3 psoriasis study. Report Dec 4, 2017 175
AbbVie meets co-primary and secondary points in three phase three trials of Risankizumab. Oct 31, 2017 185
AbbVie meets co-primary and secondary points in three phase three trials of Risankizumab. Oct 31, 2017 181
AbbVie receives Orphan Drug Designation from US FDA for risankizumab. Dec 2, 2016 213
AbbVie receives Orphan Drug Designation from US FDA for risankizumab. Dec 2, 2016 209
AbbVie awarded US FDA orphan drug designation for risankizumab for the investigational treatment of Crohn's disease in pediatric patients. Dec 1, 2016 260
AbbVie awarded US FDA orphan drug designation for risankizumab for the investigational treatment of Crohn's disease in pediatric patients. Dec 1, 2016 256

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |